Creative Antibiotics

Creativeatibiotics was founded in 2000 to commercialize world leading research at Umeå University and Karolinska Institutet. The company identifies compounds and develops candidate drugs up to and including limited clinical trials in patients. Innate develops Virulence Blocking Agents, a novel class of antibacterial drugs that may complement or replace antibiotics.

Virulence blockers disarm rather that destroy pathogenic bacteria but leave beneficial bacteria intact, which reduces the risk of the bacteria developing resistance to medicines. They may offer an advantage over conventional antibiotics as drug resistance is predicted to be less likely to develop.

Three medicines are being developed; Medicines against Diarrhoeal disease, Sexually transmitted infections and Nosocomial infections in severe burns.

Innate collaborates with an Indian company, Syngene International Ltd, in the Diarrhoea Project. In the second project, Innate is collaborating with Umeå University and University of Callifornia, Irvine, USA. The European Medicines Agency (EMEA) has designated Innate's compound INP 341 as an orphan medicinal product for the treatment of severe burns. This designation can dramatically reduce the development costs and reach the market sooner.

Innate has also a collaboration agreement with Griffith University, Brisbane, Australia. The University has built up a world-leading collection of natural produts that gives Innate the opportunity to develop novel antibacterial medicines that may represent the future of anti-bacterial therapy. A collection of 200.000 natural product fractions will be screened using Innate Pharmaceutical's platform technology to find virulence blockers. 

http://www.innate.se/